4/A: Aquestive Therapeutics SVP, Operations, Cassie Jung, Corrects Form 4 Filing Regarding Tax Withholding
SEC Filing
Cassie Jung, SVP of Operations at Aquestive Therapeutics, files an amended Form 4 to correct the number of shares withheld for tax obligations related to vesting Restricted Stock Units.
Summary
- Cassie Jung, SVP of Operations at Aquestive Therapeutics, filed an amended Form 4 on October 2, 2024, to correct a previous filing from March 12, 2024.
- The amendment concerns the number of shares withheld by Aquestive Therapeutics to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
- On March 9, 2024, 14,120 shares of common stock were withheld at a price of $4.88 per share to cover these tax obligations.
- Following the transaction, Jung directly owns 233,066 shares of Aquestive Therapeutics common stock.
- Jung also indirectly owns 2,000 shares of common stock through a spouse and 44 shares through a spouse's IRA.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 03/09/2024 | Date of transaction (shares withheld for tax obligations). |
| 03/12/2024 | Date of original Form 4 filing. |
| 10/02/2024 | Date of amended Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.